Background Heading

Discovery of therapeutics targeting
the immune tumor micro-environment
to optimize patient outcomes

iTeos is discovering a next generation of immunotherapies for cancer therapies

Cancer immunotherapy, the treatments aiming at stimulating the immune system to eliminate tumors, represents one of the most significant breakthroughs to treat cancer. However the first generation of immunotherapies: including immune checkpoint modulators, CAR T-cells, vaccines and oncolytic viruses are limited by the overall number of patients who benefit, and, for responsive patients, the depth and duration of their response. Many of these patients tumors have developed immunosuppressive mechanisms preventing activation of the immune system in the tumor microenvironment and impact the therapeutic benefit of different treatments.

To fully unlock the potential of cancer immunotherapy, iTeos develops the novel generation of immunomodulators targeting mechanisms of immune suppression, including metabolic pathways that are dysregulated in cancer and by which cancer cells evade immune destruction. 

To fully unlock the potential of cancer immunotherapy, iTeos develops the novel generation of immunomodulators targeting mechanisms of immune suppression, including metabolic pathways that are dysregulated in cancer and by which cancer cells evade immune destruction

We are building on the Ludwig Cancer Research’s fundational research in cancer immunotherapy and iTeos’ proprietary drug discovery platforms to identify novel immunosuppressive mechanisms, to be targeted to develop a new generation of  immunotherapies.

While our approaches may have clinical benefit as monotherapies, we expect that their full benefit will unfold/be fully exploited when used in combination with existing leading immunotherapies.